REGULATED PRESS RELEASE published on 07/22/2024 at 17:35, 4 months 2 days ago Disclosure of transactions in own shares on July 15 to July 19, 2024
BRIEF published on 07/16/2024 at 08:05, 4 months 8 days ago EURAZEO Announces Final Close of Transition Infrastructure Program at Over €700 Million Sustainable Investment EURAZEO ESG Impact Transition Infrastructure Program €700 Million
REGULATED PRESS RELEASE published on 07/16/2024 at 08:00, 4 months 8 days ago EURAZEO ANNOUNCES FINAL CLOSE OF ITS VERY FIRST TRANSITION INFRASTRUCTURE PROGRAM AT OVER €700 MILLION, EXCEEDING INITIAL TARGET BY 40% Eurazeo announces final close of its very first transition infrastructure program at over €700 million, exceeding initial target by 40%. The fund invests in diversified sustainable infrastructure with a focus on transitioning to a low carbon economy Sustainable Investment EURAZEO Fundraising Success Transition Infrastructure Program Low Carbon Economy
REGULATED PRESS RELEASE published on 07/15/2024 at 17:35, 4 months 9 days ago Disclosure of transactions in own shares on July 8 to July 12, 2024
BRIEF published on 07/09/2024 at 17:45, 4 months 15 days ago EURAZEO's Semi-Annual Liquidity Contract Review Liquidity Contract EURAZEO EXANE BNP PARIBAS Financial Report Semi-annual Review
REGULATED PRESS RELEASE published on 07/09/2024 at 17:40, 4 months 15 days ago Bilan semestriel – 30 juin 2024 EURAZEO's semi-annual liquidity contract balance with EXANE BNP PARIBAS as of June 30, 2024, includes 54,277 EURAZEO shares and €7,480,728, with a total of 5,087 buy transactions and 5,905 sell transactions Liquidity Contract Transactions Shares EURAZEO EXANE BNP PARIBAS
BRIEF published on 07/09/2024 at 17:40, 4 months 15 days ago Disclosure of the Number of Shares and Voting Rights as of June 30, 2024 Voting Rights Capital Shares AMF Regulation June 2024
REGULATED PRESS RELEASE published on 07/09/2024 at 17:35, 4 months 15 days ago Disclosure of the number of shares and the total number of voting rights as of June 30, 2024 Disclosure of the number of shares and voting rights of Eurazeo SE as of June 30, 2024 in compliance with French regulations Voting Rights Shares French Regulations Financial Disclosure Eurazeo SE
REGULATED PRESS RELEASE published on 07/08/2024 at 17:35, 4 months 16 days ago Disclosure of transactions in own shares on July 1 to July 5, 2024
REGULATED PRESS RELEASE published on 07/01/2024 at 17:35, 4 months 23 days ago Disclosure of transactions in own shares on June 24 to June 28, 2024
Published on 11/22/2024 at 23:55, 1 day 23 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 23 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 2 days ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 2 days ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/24/2024 at 19:16, 3 hours 58 minutes ago EQS-Adhoc: RENK Group AG: Termination of mandate of CEO Susanne Wiegand and appointment of Dr. Alexander Sagel as CEO
Published on 11/24/2024 at 19:07, 4 hours 7 minutes ago EQS-Adhoc: ABO Energy KGaA reduces forecast for the 2024 annual result to EUR 20 to 25 million and confirms market expectation for the 2025 financial year
Published on 11/22/2024 at 18:14, 2 days 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 2 days 5 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 06:58, 3 days 16 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 4 days 3 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 4 days 5 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 4 days 5 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024